- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03737708
A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)
Compare Efficacy and Safety Between Biologics + Methotrexate (MTX) vs Biologics + Tacrolimus (TAC) (Switched From Biologics + Methotrexate (MTX)) in the Patients With Rheumatoid Arthritis (RA): Randomized, Interventional, Open, Active Controlled, Parallel Group, Multicenter-designed, Phase 4 Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Daegu, Korea, Republic of
- Site KR82003
-
Daegu, Korea, Republic of
- Site KR82007
-
Daejeon, Korea, Republic of
- Site KR82006
-
Incheon, Korea, Republic of
- Site KR82002
-
Seongnam, Korea, Republic of
- Site KR82009
-
Seoul, Korea, Republic of
- Site KR82001
-
Seoul, Korea, Republic of
- Site KR82005
-
Seoul, Korea, Republic of
- Site KR82010
-
Seoul, Korea, Republic of
- Site KR82012
-
Suwon, Korea, Republic of
- Site KR82013
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with rheumatoid arthritis (RA) diagnosed by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR).
- Subjects who have been treated with combination therapy of one of biologic agent (adalimumab, tocilizumab, or abatacept) + methotrexate (MTX) over 2 months prior to Visit 1.
- Disease Activity Score (DAS28) erythrocyte sedimentation rate (ESR) ≥ 3.2 at screening and baseline.
- Subject agrees not to participate in another interventional study while participating in the present study.
Exclusion Criteria:
- Subjects with a past history of allergic reaction to Investigational Product or Comparative Drug used in this study.
- Subjects who were given tacrolimus (TAC) within three months before participation in this study.
- Subjects who have been treated with combination therapy of one of biologic agent (adalimumab, tocilizumab, or abatacept) + MTX exceeds 3 months at Baseline.
- Subjects who were already taking 20 mg of MTX at Screening Period.
- Subjects who were given the prohibited concomitant medications prior to randomization.
- Subjects with a medical history of clinically significant blood, gastrointestinal, endocrine, lung, nerve, or brain diseases at screening.
Subjects with a medical history of clinically significant liver, kidney, or heart diseases:
- Liver disease: Aspartate Aminotransferase (AST) and Alanine aminotransferase (ALT) > 3 × upper limit of normal (ULN) at screening, viral infection, nonviral infection, and liver cirrhosis;
- Kidney disease: serum creatinine > 2.0 mg/dL at screening;
- Heart disease: heart failure of ≥ The New York Heart Association class 3, arrhythmia or ischemic heart disease requiring treatment, and QTc interval > 450 ms on Electrocardiogram (ECG) at screening;
- Subjects with a history of uncontrolled diabetes (glycosylated hemoglobin > 8.5%).
- Subjects with hyperkalemia or serum potassium level > ULN of site reference ranges at screening.
- Subjects with severe respiratory disease or chronic generalized infectious disease.
- Subject who have a history of chronic infection or severe or life-threatening infection within 24 weeks before the baseline visit.
- Subject who are known to be infected by Human Immunodeficiency Virus, Hepatitis B, or Hepatitis C.
- Subject has a history of active tuberculosis or latent tuberculosis infection without treatment.
- Subject with mental disorder uncontrolled by drugs.
- Subject with chronic diarrhea, ulcerative stomatitis, gastric ulcer, or ulcerative colitis.
- Subject with genetic disorders including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
- Subject with maculopathy, retinal disorders, or clinically significant eye diseases that may lead to visual disorder.
- Subject with bone marrow disorder, leukopenia, and blood cell disorder such as severe anemia and thrombocytopenia.
- Subject with a history of major surgery within 12-weeks before screening.
- Subject who were diagnosed with malignant tumors within 5 years before screening or who need treatment for malignant tumors diagnosed in the past.
- Patients with basal cell and squamous cell carcinomas of the skin or carcinoma in situ of the cervix uteri that has been excised and cured, may be included on the study at the discretion of the investigator.
- Female subject who is positive for the serum pregnancy test at Visit 1 among a woman of childbearing potential (WOCBP) (menopausal is defined as amenorrhea for at least one year) or not surgically sterile, or is not willing to use appropriate contraception during the study. Female subject trying to become pregnant or is currently pregnant or breast feeding.
- Male subject who donates sperm during the treatment period and for at least 30 days whichever is longer after the final study drug administration.
- Male subject with a pregnant or breastfeeding partner(s) who do not agree to remain abstinent or use a condom for the duration of the pregnancy, or for the time partner is breastfeeding, throughout the study period and for 30 days whichever is longer after the final study drug administration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: tacrolimus + biologics
Participants will receive tacrolimus daily for 12 weeks.
In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
|
Administered orally
Other Names:
Administered as subcutaneous injection
Administered by intravenous injection
Administered by intravenous injection
|
Active Comparator: methotrexate + biologics
Participants will receive methotrexate weekly for 12 weeks.
In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
|
Administered as subcutaneous injection
Administered by intravenous injection
Administered by intravenous injection
Administered orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in disease activity score 28 (DAS28) erythrocyte sedimentation rate score (ESR) score at 12 weeks
Time Frame: From baseline (week 1) to week 12
|
DAS28-ESR will be calculated using data from tender joint count (TJC) (28 joints), swollen joint count (SJC) (28 joints), ESR and Subject's Global Assessment of Arthritis (SGA) with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x SGA. High disease activity: DAS28 score exceeding 5.1 Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1 Low disease activity: DAS28 score of less than or equal to 3.2 If the DAS28 score is less than 2.6, the participant will be considered to be in DAS28 remission. |
From baseline (week 1) to week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease activity score 28 (DAS28) erythrocyte sedimentation rate (ESR) rate score at 4 weeks
Time Frame: At 4 weeks
|
DAS28-ESR will be calculated using data from TJC (28 joints), SJC (28 joints), ESR and SGA with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x SGA. High disease activity: DAS28 score exceeding 5.1 Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1 Low disease activity: DAS28 score of less than or equal to 3.2 If the DAS28 score is less than 2.6, the participant will be considered to be in DAS28 remission. |
At 4 weeks
|
DAS28 (ESR) score at 8 weeks
Time Frame: At 8 weeks
|
DAS28-ESR will be calculated using data from TJC (28 joints), SJC (28 joints), ESR and SGA with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x SGA. High disease activity: DAS28 score exceeding 5.1 Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1 Low disease activity: DAS28 score of less than or equal to 3.2 If the DAS28 score is less than 2.6, the participant will be considered to be in DAS28 remission. |
At 8 weeks
|
DAS28 (ESR) score at 12 weeks
Time Frame: At 12 weeks
|
DAS28-ESR will be calculated using data from TJC (28 joints), SJC (28 joints), ESR and SGA with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x SGA. High disease activity: DAS28 score exceeding 5.1 Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1 Low disease activity: DAS28 score of less than or equal to 3.2 If the DAS28 score is less than 2.6, the participant will be considered to be in DAS28 remission. |
At 12 weeks
|
Change in DAS28 (ESR) score at 4 weeks
Time Frame: From baseline (week 1) to week 4
|
DAS28-ESR will be calculated using data from TJC (28 joints), SJC (28 joints), ESR and SGA with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x SGA. High disease activity: DAS28 score exceeding 5.1 Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1 Low disease activity: DAS28 score of less than or equal to 3.2 If the DAS28 score is less than 2.6, the participant will be considered to be in DAS28 remission. |
From baseline (week 1) to week 4
|
Change in DAS28 (ESR) score at 8 weeks
Time Frame: From baseline (week 1) to week 8
|
DAS28-ESR will be calculated using data from TJC (28 joints), SJC (28 joints), ESR and SGA with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x SGA. High disease activity: DAS28 score exceeding 5.1 Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1 Low disease activity: DAS28 score of less than or equal to 3.2 If the DAS28 score is less than 2.6, the participant will be considered to be in DAS28 remission. |
From baseline (week 1) to week 8
|
ACR 20 response rate
Time Frame: At 12 weeks
|
Percent of participants with American College of Rheumatology (ACR) 20 response rate The ACR20 response requires that all criteria from (1) to (3) be met compared with Week 0 (baseline); (1), Tender Joint Count (TJC) >= 20% reduction; (2), Swollen Joint Count (SJC) >= 20% reduction;(3) >= 20% improvement in three or more of the following five parameters - [1] subject's assessment of pain, [2] Subject's Global Assessment of Arthritis (SGA), [3] Physician's Global Assessment of Arthritis (PGA), [4] health assessment questionnaire-disability index (HAQ-DI), [5] acute phase reactant (erythrocyte sedimentation rate (ESR)).
|
At 12 weeks
|
ACR50 response rate
Time Frame: At 12 weeks
|
Percent of participants with ACR50 response rate The ACR50 response indicates a 50% improvement in all criteria used in the ACR20 assessment.
|
At 12 weeks
|
ACR70 response rate
Time Frame: At 12 weeks
|
Percent of participants with ACR70 response rate The ACR70 response indicates a 70% improvement in all criteria used in the ACR70 assessment.
|
At 12 weeks
|
Safety assessed by Adverse Events (AEs)
Time Frame: Up to 16 weeks
|
An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.
|
Up to 16 weeks
|
Safety assessed by incidence of serious adverse events (SAE)
Time Frame: Up to 16 weeks
|
Adverse Event (AE) is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event.
|
Up to 16 weeks
|
Safety assessed by incidence of treatment emergent adverse events (TEAE)
Time Frame: Up to 12 weeks
|
Treatment Emergent Adverse Event (TEAE) is defined as any AE which starts, or worsens, after the first dose of study drug through 30 days after the last dose of study drug.
|
Up to 12 weeks
|
Number of participants with laboratory value abnormalities and/or adverse events (AEs)
Time Frame: Up to 16 weeks
|
Number of participants with potentially clinically significant laboratory values.
|
Up to 16 weeks
|
Number of participants with vital sign abnormalities and /or adverse events (AEs)
Time Frame: Up to 16 weeks
|
Number of participants with potentially clinically significant vital sign values.
|
Up to 16 weeks
|
Number of participants with physical exam abnormalities and/or adverse events (AEs)
Time Frame: Up to 16 weeks
|
Number of participants with potentially clinically significant physical exam values.
|
Up to 16 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Immune Checkpoint Inhibitors
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Calcineurin Inhibitors
- Adalimumab
- Methotrexate
- Tacrolimus
- Abatacept
Other Study ID Numbers
- 506-MA-3187
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis (RA)
-
SinoMab BioScience LtdRecruitingRheumatoid Arthritis(RA)China
-
Veena Ranganath, MD, MSRecruiting
-
AbbVieActive, not recruitingRheumatoid Arthritis (RA)Argentina, Australia, Austria, Belgium, France, Germany, Greece, Ireland, Israel, Italy, Kuwait, Mexico, Russian Federation, Saudi Arabia, Spain, Switzerland, Taiwan, United Arab Emirates, Uruguay
-
Astellas Pharma China, Inc.CompletedRheumatoid Arthritis (RA)China, Korea, Republic of, Taiwan
-
Jiangsu HengRui Medicine Co., Ltd.CompletedRheumatoid Arthritis (RA)China
-
Faiq GorialCompleted
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Bristol-Myers SquibbUnknown
-
medac GmbHPPDCompletedRheumatoid Arthritis (RA)United States
-
Antares Pharma Inc.CompletedRheumatoid Arthritis (RA)United States
-
Chugai Pharma TaiwanCompletedRheumatoid Arthritis (RA)Taiwan
Clinical Trials on tacrolimus
-
Novartis PharmaceuticalsCompletedLiver Transplant RecipientBelgium, Spain, Germany, Italy, Australia, United States, Netherlands, Ireland, Sweden, Brazil, Colombia, France, Russian Federation, Argentina, Czechia, United Kingdom
-
Novartis PharmaceuticalsCompletedLiver TransplantationUnited States, Belgium, Colombia, Spain, Germany, Italy, Australia, Israel, France, Hungary, Netherlands, Argentina, Canada, Ireland, Sweden, Brazil, United Kingdom, Russian Federation, Czech Republic
-
Astellas Pharma IncAstellas Pharma Korea, Inc.CompletedLiver TransplantationKorea, Republic of
-
Heleen GrootjansChiesi Farmaceutici S.p.A.RecruitingLung Transplant; ComplicationsNetherlands
-
The Methodist Hospital Research InstituteVeloxis PharmaceuticalsWithdrawnAcute Rejection of Renal Transplant | Kidney Disease, End-Stage | Donor Specific Antibodies
-
Taro Pharmaceuticals USACompleted
-
Peking Union Medical College HospitalUnknown
-
Technical University of MunichCompleted
-
University of British ColumbiaPaladin Labs Inc.RecruitingLiver Transplantation | Neurotoxicity | Tremor | Tacrolimus | ImmunosuppressionCanada
-
Limerick BioPharmaCompleted